61th European Renal Association (ERA) Congress - Prof. K. R. Tuttle, Dr. V. Luyckx, Prof. T. Huber

In a special webinar in cooperation between MARKUS @ HOMe and Nephrology, Dialysis and Transplantation - NDT, the official journal of the European Renal Association (ERA), Prof. Katherine Tuttle, Dr. Valerie Luyckx and Prof. Tobias Huber discuss landmark studies that have been presented at the ERA 2024 convention in Stockholm, Sweden.

Dr. Tuttle is Clinical Professor of Medicine at UW Medicine, Division of Nephrology, Seattle, WA, and Professional Executive Director for Research at Providence Health Care, Spokane, WA.

Dr. Valerie Luyckx is Nephrologist at Zurich Kidney Center, Zurich, Switzerland, and Chair of the Advocacy Committee of the International Society of Nephrology.

Dr. Tobias Huber is Professor of Nephrology and Director of the III. Department of Medicine, at UKE, Hamburg, Germany.

The interview was recorded on May 27st, 2024.

Moderators: Prof. Dr. Marcus Säemann (Vienna, Austria), Prof. Dr. Andreas Kronbichler (Innsbruck, Austria) and Prof. Dr. Gunnar Heine (Frankfurt, Germany).

Articles discussed:

Autoantibodies Targeting Nephrin in Podocytopathies
Hengel FE, …, Tomas NM, Huber TB
N Engl J Med 2024
DOI: 10.1056/NEJMoa231447

Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
Perkovic V, Tuttle KR et al.
N Engl J Med 2024
DOI: 10.1056/NEJMoa2403347

A Randomized Phase 2 Trial of Felzartamab in Antibody-Mediated Rejection
Mayer KA, …, Böhmig GA
N Engl J Med 2024
DOI: 10.1056/NEJMoa2400763

Unraveling the mechanisms of glomerular ultrafiltration: nephrin, a key component of the slit diaphragm.
Tryggvason K
J Am Soc Nephrol 1999
doi: 10.1681/ASN.V10112440

Management of adult patients with podocytopathies: an update from the ERA Immunonephrology Working Group.
Mirioglu S, Daniel-Fischer L, Berke I, Ahmad SH, Bajema IM, Bruchfeld A, Fernandez-Juarez GM, Floege J, Frangou E, Goumenos D, Griffith M, Moran SM, van Kooten C, Steiger S, Stevens KI, Turkmen K, Willcocks LC, Kronbichler A.
Nephrol Dial Transplant 2024
doi: 10.1093/ndt/gfae025

Felzartamab (anti-CD38) in patients with IgA Nephropathy—interim results from the IGNAZ study
Floege J et al.
Nephrol Dial Transplant Suppl
https://doi.org/10.1093/ndt/gfae069.139

Albuminuria predicts kidney events in IgA nephropathy.
Faucon AL, Lundberg S, Lando S, Wijkström J, Segelmark M, Evans M, Carrero JJ.
Nephrol Dial Transplant 2024
doi: 10.1093/ndt/gfae085

An antigen-specific chimeric autoantibody receptor (CAAR) NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells.
Seifert L, Riecken K, Zahner G, Hambach J, Hagenstein J, Dubberke G, Huber TB, Koch-Nolte F, Fehse B, Tomas NM.
Kidney Int 2024
doi: 10.1016/j.kint.2024.01.021

Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology.
Watts AJB, Keller KH, Lerner G, Rosales I, Collins AB, Sekulic M, Waikar SS, Chandraker A, Riella LV, Alexander MP, Troost JP, Chen J, Fermin D, Yee JL, Sampson MG, Beck LH Jr, Henderson JM, Greka A, Rennke HG, Weins A.
J Am Soc Nephrol 2022
doi: 10.1681/ASN.2021060794